Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antigen-Free Screening Finds Antibody Biomarkers For Alzheimer's Diagnosis

This article was originally published in Start Up

Executive Summary

Use of a library of synthetic peptide-like molecules as a screen to identify disease-specific antibodies in serum has led to identification of biomarkers for Alzheimer's disease that could form the basis of a blood-based diagnostic test. The screening strategy may also be broadly applicable to the development of diagnostics for other diseases, for identifying antibody targets in autoimmune diseases, and even as the basis for vaccine development.

You may also be interested in...



Alzheimer's Dx: An Essential Piece of the Puzzle

Finding growth opportunities in an era of constrained spending and health care reform is not an easy task, but an increasing number of companies operating in the diagnostics space are taking aim at one underserved area they believe will be a big winner in the years ahead: Alzheimer’s disease. This is a field still in its infancy and the risk of failure remains high. But as research progresses, it’s becoming clear that advances in AD diagnostics could play a major role in reducing that risk.

New Alzheimer's Disease Target and a Potentially Broad Drug Discovery Approach

Researchers have identified a new target in Alzheimer's disease--the natural substrate of an enzyme that itself has long been a target for AD drug development. That the molecule appears to be druggable is itself a surprising observation that may offer valuable insight into how to improve AD drugs. More than that, however, it suggests that substrates of protease inhibitors may provide a completely new set of drug targets in a variety of diseases.

Science Matters: Welcome To The Oncobiome

A new publication offers up proof of concept that the genetic signatures of microorganisms found in blood and tumor tissue could improve precision medicine cancer diagnostics. The study also bolsters the notion that targeting the microbiome could lead to innovative cancer therapies.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

ID034708

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel